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Abstract: The secreted Mac protein made by group A Streptococcus (GAS) inhibits opsonophagocytosis of GAS by  
human polymorphonuclear leukocytes (PMNs). This protein also has the endopeptidase activity against human   
immunoglobulin G (IgG), and the Cys94, His262 and Asp284 are critical for the enzymatic activity. The horse pathogen 
Streptococcus equi subspecies equi produces a homologue of Mac (SeMac). SeMac was characterized to determine 
whether SeMac has IgG endopeptidase activity and inhibits opsonophagocytosis of S. equi by horse PMNs. The gene  
was cloned and recombinant SeMac was overexpressed in Escherichia coli and purified to homogeneity. Mice with   
experimental S. equi infection and horses with strangles caused by S. equi seroconverted to SeMac, indicating that SeMac 
is produced in vivo during infection. SeMac has endopeptidase activity against human IgG. However, the protein just 
cleaves a small fraction, which may be IgG1 only, of horse IgG. Replacement of Cys102 with Ser or His272 with Ala 
abolishes the enzymatic activity of SeMac, and the Asp294Ala mutation greatly decreases the enzymatic activity. SeMac 
does not inhibit opsonophagocytosis of S. equi by horse PMNs but opsonophagocytosis of GAS by human PMNs. Thus, 
SeMac is a cysteine endopeptidase with a limited activity against horse IgG and must have other function. 
Keywords: IgG, Endopeptidase SeMac, opsonophagocytosis, polymorphonuclear leukocytes.  
INTRODUCTION 
 Gram-positive  bacterium  Streptococcus equi subspeices 
equi (S. equi) causes equine strangles, a highly contagious 
purulent lymphadenitis and one of the most common infec-
tious diseases in horses [1,2]. The infection initially causes 
nasal discharge and fever and, then, leads to abscess forma-
tion in local lymph nodes, causing enormous pain and respi-
ratory difficulty. There is massive infiltration of polymor-
phonuclear leukocytes (PMNs) to the infection site. How-
ever, S. equi effectively evades the horse innate immunity by 
being resistant to phagocytosis by PMNs. Horses recovered 
from strangles acquire immunity against S. equi reinfection 
[3]. The immunity is primarily mediated by protective anti-
bodies [4], which opsonize and thus enhance phagocytosis of 
S. equi by horse PMNs. 
  To survive in hosts, bacterial pathogens have evolved 
multiple mechanisms to evade host defense. For examples, 
both S. equi and group A Streptococcus (GAS) produce the 
hyaluronic acid capsule and surface protein M protein to 
contribute to resistance to phagocytosis by PMNs. We found 
that GAS produces a secreted Mac protein (also known as 
IdeE), which inhibits opsonophagocytosis of GAS by human 
PMNs [5]. This protein can cleave the heavy chain of human 
immunoglobulin G (IgG) using Cys94, His262 and Asp284 
as its catalytic triad [6-8]. There are two kinds of Mac   
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produced by GAS isolates [7], which use different mecha-
nisms to block the interaction between IgG and Fc receptor 
on the surface of PMNs. The type-1 Mac, such as M1 Mac  
produced by serotype M1 GAS strains, has high enzymatic 
activity and low affinity to Fc receptor on the surface of 
PMNs, while the type-2 Mac can bind to the Fc receptor   
and has lower enzymatic activity [9]. S. equi has a homo-
logue of GAS M1 Mac (designated SeMac). In this study, 
SeMac was prepared and characterized. The results indicate 
that SeMac is a cysteine endopeptidase but does not inhibit 
opsonophagocytosis of S. equi by horse PMNs, suggesting 
that SeMac has function other than evading horse acquired 
immunity against S. equi infection. 
MATERIALS AND METHODS 
Materials 
  Purified horse IgG1 and a mixture of horse IgG1 and 
IgG4 were kindly provided by Dr. Bettina Wagner at Cornell 
University. S. equi-specific mouse sera were obtained from 
adult female outbred CD-1 Swiss mice (Charles River Labo-
ratories, Wilmington, Mass.) 21 days after they were inocu-
lated subcutaneously with 1 x 10
7 cfu S. equi strain SEM1. 
Convalescent sera from 3 horses suffering from strangles 
were obtained 30 days after diagnosis. GAS M1 Mac was 
prepared as previously described [5]. 
Bacterial Strains and Growth 
  Six of 10 S. equi strains used were kindly provided by 
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and these strains were isolated more than 20 years ago from 
horses with strangles in the Eastern U.S. (4 strains), Brazil (1 
strain), and Finland (1 strain). The other 4 strains were iso-
lated in 2003 from horses with strangles in Livingston (des-
ignated strain SEM1) [10], Pony, Great Fall, and Norris in 
Montana. GAS strain MGAS5005 (serotype M1) has been 
described [11]. Escherichia coli Novablue and BL21(DE3) 
(Novagen, Madison, Wis.) were used for gene cloning and 
protein expression, respectively. S. equi and GAS strains 
were routinely grown in Todd-Hewitt broth (Difco Laborato-
ries, Detroit, Mich.) supplemented with 0.2% yeast extract 
(THY) in 5% CO2 at 37°C. THY agar and tryptose agar with 
5% sheep blood (Becton Dickinson, Cockeysville, Md.) were 
used as the solid media. 
Gene Cloning and Mutagenesis 
  The gene fragment encoding mature SeMac was cloned 
from SEM1 with primers 5’-ACCATGGACGA TTAC-
CAAAGGAATGCTAC-3’ and 5’-CGAATTCT TAGCT- 
CAGTTTCTGCCATATG-3’. The protein made from this 
cloned fragment lacks the presumed secretion signal   
sequence (amino acids 1-34). The PCR product was digested 
with NcoI and EcoRI and ligated into pET-21d (Novagen) to 
yield recombinant plasmid pSEMAC. The cloned gene was 
sequenced and had identical DNA sequence with the corre-
sponding open reading frame of S. equi genome database 
[12]. Amino acid replacement of Cys102 and His272 or 
Asp294 of SeMac with serine and alanine, respectively,   
was achieved by site-directed mutagenesis using the Quick-
Change Mutagenesis kit (Stratagene, La Jolla, Calif.). The 
entire mutated gene was sequenced to confirm the mutations 
and rule out spurious mutations. 
Expression and Purification of Recombinant SeMac 
  Recombinant SeMac was purified from E. coli BL21 
(DE3) containing plasmid pSEMAC. Bacteria were grown to 
optical density at 600 nm of 0.5 in 6 liters of Luria-Bertani 
broth supplemented with 100 mg of ampicillin per liter at 
37°C, and SeMac expression was then induced with 0.5 mM 
IPTG 6 h. Solutions used in purification were buffered with 
10 mM Tris-HCl (pH 8.0). Cell paste was sonicated for 15 
min at 4°C in 60 ml of the buffer, and centrifuged at 15,000 
g for 10 min. The supernatant obtained was loaded onto a 
DEAE-Sepharose column (2.5 by 10 cm). The column was 
washed with 50 ml of Tris-HCl, and SeMac was eluted with 
200 ml of 50 mM NaCl. SeMac was identified by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), and peak fractions were pooled. Ammonium sulfate 
was added to the pool to a concentration of 1.2 M, and the 
resulting solution was applied to a phenyl-Sepharose column 
(1.5 x 10 cm). The column was washed with 50 ml of 1.2 M 
(NH4)2SO4 and eluted with a 100-ml linear gradient of 1.2 to 
0.7 M (NH4)2SO4. Fractions containing the protein were 
pooled. The pooled protein was precipitated with (NH4)2SO4 
at 70% of saturation, centrifuged, dialyzed against 3 liters of 
10 mM Tris-HCl buffer (pH 8.0) overnight, and loaded onto 
a DEAE-Sepharose column (1.5 by 10 cm). The protein was 
eluted with a 100-ml linear gradient of 2 to 8 mM NaCl and 
pooled. The pooled protein was concentrated by (NH4)2SO4 
precipitation and dialyzed against Tris-HCl as described 
above. 
DNA Sequencing 
  Genomic DNA was isolated with a FastDNA SPIN Kit 
(Qbiogene, Calsdad, Calif.) according to manufacturer’s 
protocol. A DNA fragment containing S. equi mac was am-
plified by PCR using the genomic DNA samples and primers 
5’-GCATCTCTACTATCTCATCAC-3’ and 5’-ACAGGC- 
ACATTAATGTTTAAC-3’. Sequences of the PCR products 
were obtained from both DNA strands with an Applied Bio-
system 310 automated sequencer (Applied BioSystems, Inc., 
Foster City, Calif.). 
Anti-SeMac antisera 
  Four female outbred CD-1 Swiss mice (4-week-old) 
(Charles River Laboratories) were immunized subcutane-
ously with 50 g of recombinant SeMac suspended in 200 l 
of saline emulsified in 44 l of monophosphoryl lipid A-
synthetic trehalose dicorynomycolate adjuvant (Corixa, 
Hamilton, Mont.). The animals were anesthetized by isoflu-
rane inhalation prior to immunization and blood collection. 
Blood was collected prior to active immunization to prepare 
control sera. Mice were boosted at weeks 2 and 4 with 50 g 
of protein mixed with the adjuvant. Anti-SeMac antiserum 
was prepared from blood obtained 1 week after the second 
booster. 
Phagocytosis Assay 
  Phagocytosis assay was performed as described previ-
ously [13, 14]. Briefly, S. equi SEM1 and GAS bacteria from 
exponential growth phase in THY were washed with phos-
phate-buffered saline (PBS) and labeled with 0.75 μg/ml 
FITC in PBS at 37°C for 20 min. The labeled bacteria were 
washed and resuspended at 1 x 10
9 cfu/ml in PBS. Ten μl of 
the labeled bacteria were mixed with 100 μl of non-immune 
heparinized horse or human blood with or without 100 μg/ml 
SeMac and incubated with gentle shaking at 37°C for 5, 10, 
or 20 min. The samples were immediately processed using 
an Immunolyse Kit (Beckman Coulter) according to the 
manufacturer’s protocol and analyzed by flow cytometry. 
The percentage of PMNs with fluorescent bacteria was used 
as a measure of phagocytosis efficiency. 
Other Assays  
  To assess IgG endopeptidase activity of SeMac, human, 
mouse or horse IgG (20 μg) was incubated with E. coli lysate 
containing SeMac proteins or 1 μg purified SeMac or GAS 
M1 Mac in PBS at 37° for 90 min, and the reaction mixture 
was analyzed by SDS-PAGE. Western immunoblot analysis, 
which was performed as described previously [15], was used 
to assess in vitro SeMac production and the presence of Se-
Mac-specific antibody in the horse and mouse convalescent 
sera. Culture supernatant proteins of S. equi, which were 
used to assess the in vitro SeMac production, were prepared 
by the method of Lei et al. [16]. 
RESULTS 
S. equi Mac Gene 
 S.  equi genome encodes a Mac homologue SeMac. The 
protein shares 62.4% identity in amino acid sequence with 
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signal sequence (amino acids 1-34), and the catalytic resi-
dues of GAS Mac consisting of Cys94, His262 and Asp284 
are conserved in SeMac (Cys102, His272 and Asp 294) (Fig. 
1). To test whether other S. equi strains have the mac gene, 
10 S. equi isolates representing various geographic locations 
were tested with PCR using mac-specific primers. All the 
strains tested had the mac gene (Fig. 2). DNA sequencing 
found that the mac gene is 100% conserved in DNA   
sequence in these strains. 
Recombinant SeMac and In Vitro and In Vivo Expression 
of SeMac 
  To characterize SeMac, the fragment of S. equi mac gene 
encoding mature SeMac was cloned, and recombinant   
SeMac was purified to >95% purity as assessed by SDS-
PAGE (Fig. 3A). To assess the in vitro production of SeMac, 
culture supernatant of the 10 S. equi strains was prepared by 
the method of Lei et al. [16], resolved by SDS-PAGE, and 
probed by Western immunoblot with anti-SeMac mouse   
antisera. No SeMac was detected in all the samples (data   
not shown), suggesting that SeMac is not produced in vitro. 
To test whether SeMac is produced in vivo during S. equi 
infection, the presence of SeMac-specific antibody was   
assessed by Western immunoblot analysis with convalescent 
sera from 3 horses suffered from strangles and mice with 
experimental  S. equi infection. All the convalescent sera 
tested had SeMac-specific antibody (Fig. 3B), indicating that 
SeMac is produced in vivo during infection. 
Endopeptidase Activity of SeMac against Horse IgG1 
and Human IgG 
  GAS Mac can cleave the heavy chain of human IgG at 
the lower hinge region between Fab and Fc fragments. A 
catalytic triad of Cys94, His262, and Asp284 residues is 
critical for the enzymatic activity of GAS Mac [7, 8]. SeMac 
possesses putative catalytic residues of Cys102, His272, and 
Asp294 (Fig. 1). To determine whether SeMac also is a cys-
teine endopeptidase targeting IgG, Cys102 and His272 or 
Asp294 of SeMac were replaced with Ser and Ala, respec-
tively, by site-directed mutagenesis, and wild-type and mu-
tant (SeMac
Cys102Ser, SeMac
His272Ala and SeMac
Asp294Ala)  
SeMac proteins expressed in E. coli were tested for IgG en-
dopeptidase activity using human IgG. Wild-type SeMac 
cleaved the heavy chain of human IgG, while SeMac
Cys102Ser 
and SeMac
His272Ala completely lost the IgG endopeptidase 
activity, and SeMac
Asp294Ala had dramatically lower enzy-
matic activity than the wild-type protein (Fig. 4A). The re-
sults indicate that SeMac is a cysteine endopeptidase, which 
uses Cys102, His272 and Asp294 as its catalytic triad to 
cleave human IgG. 
 
 
 
 
 
 
 
Fig. (2). Detection of S. equi mac gene in clinical isolates by 
PCR. The picture shows the mac PCR product amplified from 10 S. 
equi isolates from horses suffering from strangles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Recombinant SeMac and evidence for in vivo produc-
tion of SeMac. (A) SDS-PAGE analysis of recombinant SeMac. 
Lanes: 1, E. coli lysate without SeMac (control); 2, E. coli lysate 
containing overexpressed SeMac; 3, purified SeMac. (B) Western 
immunoblot analysis of SeMac with SeMac antibody present in the 
convalescent-phase sera from 3 horses with S. equi infection (eC1, 
eC2, eC3) and mice before (mP) and after (mC) experimental S. 
equi infection. 
 
 
 
 
 
Fig. (1). Amino acid sequence alignment of SeMac and GAS M1 Mac. The conserved Cys (C), His (H), and Asp (D) constituting the cata-
lytic triad are highlighted in red and underlined. Amino acid residues of GAS Mac identical to those in SeMac (·) and gaps introduced to 
maximize alignment (-) are indicated. The arrow indicates the presumed cleavage site of the secretion signal sequence. 
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  Purified recombinant SeMac and GAS Mac were then 
tested for activity to cleave horse IgG. While both proteins 
cleaved human IgG efficiently, only a small fraction of horse 
IgG was cleaved by either protein (Fig. 4B), suggesting that 
SeMac or GAS Mac cannot digest all subgroups of horse 
IgG. To test this possibility, available horse IgG1 and a mix-
ture of IgG1 and IgG4 were treated with SeMac or GAS 
Mac. SeMac or GAS Mac cleaved a small portion of the 
IgG1/IgG4 mixture, but not IgG4. Therefore, the Mac pro-
teins can cleave IgG1 but not IgG4. Due to the unavailability 
of other purified subgroup IgG, it is not known whether Se-
Mac cleaves the other IgG subgroups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). IgG endopeptidase activity of SeMac. (A) IgG-
endopeptidase activity and critical amino acid residues for activity. 
Human IgG was incubated without (none) or with E. coli lysate 
containing wild-type SeMac (wt), SeMac
Cys102Ser (C102S), Se-
Mac
His272Ala, or SeMac
Asp294Ala at room temperature for 60 min and 
analyzed by SDS-PAGE. (B) Limited cleavage of horse IgG by 
SeMac and GAS Mac. Horse total IgG (eIgG), IgG4 (eIgG4), 
IgG1/IgG4 mixture (eIgG1/4), or human IgG was incubated with 
purified SeMac or GAS M1 Mac and analyzed by SDS-PAGE. 
SeMac does not Inhibit Opsonophagocytosis of S. equi by 
Horse PMN 
  A whole blood based phagocytosis assay [13, 14] was 
used to test whether SeMac inhibits opsonophagocytosis of 
S. equi by horse PMNs. The bacteria were labeled with 
FITC, treated with S. equi-specific horse convalescent serum 
in the absence or presence of SeMac, and incubated with 
horse blood. Percentage of PMNs with phagocytosed S. equi 
was determined by flow cytometry. As expected, percentage 
of PMNs with phagocytosed S. equi with the serum treat-
ment was significantly higher than that for S. equi without 
serum treatment. But the inclusion of SeMac in the assay did 
not affect opsonophagocytosis of S. equi (Fig. 5A), suggest-
ing that SeMac does not inhibit opsonophagocytosis of S. 
equi by horse PMNs. 
  The inability of SeMac to inhibit S. equi opsonophagocy-
tosis by horse PMNs may be due to its inability to cleave the 
majority of horse IgG. If this is true, SeMac should inhibit 
opsonophagocytosis of GAS by human PMNs, since SeMac 
efficiently cleaves human IgG. To test this idea, the phago-
cytosis assay was repeated using GAS and human blood. 
SeMac indeed inhibits the opsonophagocytosis of GAS by 
human PMNs (Fig. 5B). These results suggest that IgG en-
dopeptidase activity of SeMac is critical for inhibition of 
phagocytosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Effects of SeMac on opsonophagocytosis of S. equi and 
GAS by horse (A) and human (B) PMNs, respectively. FITC-
labeled S. equi and GAS bacteria (10
7 c.f.u.) were treated without or 
with horse and human convalescent sera and incubated in the pres-
ence or absence of 100 μg/ml SeMac with 100 μl nonimmune horse 
and human blood, respectively, at 37°C for 5, 10 or 20 min. Red 
blood cells were lysed using an Immunolyse kit, and percentages of 
PMNs with phagocytosed bacteria determined by flow cytometry 
are presented. 
DISCUSSION 
  In this study we describe that SeMac is a cysteine en-
dopeptidase with limited activity against horse IgG and is 
unable to inhibit opsonophagocytosis of S. equi by horse 
PMNs in a whole blood assay. SeMac efficiently cleaves the 
heavy chain of human IgG. The residues of Cys102 and 
His272 are essential and Asp294 important for the enzymatic 
activity of SeMac. Thus, like GAS M1 Mac [7,8], SeMac is 
a cysteine endopeptidase. Although both SeMac and GAS 
Mac efficiently cleave human IgG, they cannot cleave the 
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majority of total horse IgG. The peptide fragment, PELLGG, 
in the lower hinge region is proposed to bind to the active 
site of Mac [9], and the cleavage occurs between the two Gly 
residues (Table 1). This lower hinge region is not well con-
served in the seven subgroups of horse IgG [17] (Table 1). 
Cleavable horse IgG1 has PELLGG, while the non-cleavable 
horse IgG4 has PECLSVG in the same region, suggesting 
that the amino acid sequences of the lower hinge region are 
important for cleavability by SeMac and GAS Mac. If this is 
true, horse IgG3 may be also cleavable by SeMac, while the 
other five horse IgG subgroups may not be cleaved. These 
horse IgG antibodies that cannot be cleaved by SeMac thus 
still can mediate the opsonophagocytosis of S. equi. 
  SeMac and GAS M1 Mac show similar enzymatic speci-
ficity (Fig. 4 and Table 1), confirming the previous finding 
[18]. SeMac can cleave human IgG and inhibit the opsono-
phagocytosis of GAS by human PMNs, but it has limited 
enzymatic activity against horse IgG and is unable to inhibit 
opsonophagocytosis of S. equi by horse PMNs. Thus, there  
is a correlation between the enzymatic activity of SeMac   
and its ability to inhibit opsonophagocytosis, suggesting   
that SeMac functions like GAS M1 Mac in the inhibition of 
opsonophagocytosis of GAS by human PMNs. 
 Timoney  et al. recently reported that IdeE/SeMac   
reduces the bactericidal activity of isolated equine PMNs   
for  S. equi [19]. Our results suggest that the inhibition   
of the bactericidal activity of PMNs may not be mediated by 
opsonophagocytosis or may be insignificant in whole blood. 
  SeMac is not produced in vitro, whereas GAS Mac is 
[16]. The mac gene is controlled by the two-component 
regulatory system CovRS [5], which also controls the ex-
pression of many virulence factors including the hyaluronic 
capsule [20]. The hyaluronic capsule of S. equi is highly 
produced in vitro. These observations suggest that the semac 
and mac genes are regulated by different mechanisms. This 
suggestion is supported by only 29% DNA sequence identity 
between S. equi and M1 GAS in the upstream region of the 
semac and mac genes. 
 S.  equi is a horse pathogen. The fact that SeMac does not 
inhibit opsonophagocytosis of S. equi by horse PMNs indi-
cates that SeMac is not involved in the evasion of the ac-
quired horse immunity against S. equi. This suggests that 
SeMac has other unknown function.  
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